{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-001049","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.068345+00:00","generated_at":"2026-06-06T00:11:08.568485+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Majority shareholder approves warrant adjustments for Sunshine Biopharma","bullets":["Dr. Steve Slilaty (CEO, 58.3% voting power) approved written consent on Feb 13, 2024.","Consent covers alternative cashless exercise for Series A Warrants and adjustments upon share combination.","Also includes voluntary exercise price adjustments, Floor Price clause inapplicability for Series B, and dilutive issuance adjustments.","Effective 20 days after mailing information statement to shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-001049","json":"https://secwatch.observer/filing/0001683168-24-001049.json","markdown":"https://secwatch.observer/filing/0001683168-24-001049.md","text":"https://secwatch.observer/filing/0001683168-24-001049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:11:08.568485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2367b28620e85d9bf4cfb6d19ab6c6308b3b9603","claim":"Sunshine Biopharma Inc. shareholders approved Voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding Warrants pursuant to Section 3.8 of the Series A Warrants and 3.9 of the Series B Warrants at the 2024-02-13 meeting.","evidence_excerpt":"On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-02-13"}],"fact_type":"shareholder_vote"},{"claim_id":"9a862a662619143b1241fcf06728cd69af18baae","claim":"Sunshine Biopharma Inc. shareholders approved Give full effect to the adjustment in the exercise price and number of Warrant Shares as defined in the Series B Warrants following a Dilutive Issuance as defined in the Series B Warrants pursuant to Section 3.2 of the Series B Warrants at the 2024-02-13 meeting.","evidence_excerpt":"On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-02-13"}],"fact_type":"shareholder_vote"},{"claim_id":"abbb9a191a83bc45f87f957f92414a576875e4c4","claim":"Sunshine Biopharma Inc. shareholders approved Give full effect to alternative cashless exercises pursuant to Section 2.3 of the Series A Warrants at the 2024-02-13 meeting.","evidence_excerpt":"On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-02-13"}],"fact_type":"shareholder_vote"},{"claim_id":"ac428600a6c49534af480231d37b104488d69c00","claim":"Sunshine Biopharma Inc. shareholders approved Any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants in the event of a Share Combination Event as defined in the Series A Warrants and Series B Warrants in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warra at the 2024-02-13 meeting.","evidence_excerpt":"On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-02-13"}],"fact_type":"shareholder_vote"},{"claim_id":"da08a6373432f4cf2f003421be2839f195d386d5","claim":"Sunshine Biopharma Inc. shareholders approved Render inapplicable clause (i) of the definition of the Floor Price as defined in the Series B Warrant in Section 3.2 of the Series B Warrants at the 2024-02-13 meeting.","evidence_excerpt":"On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-02-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}